Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
A high-level committee recommended a new institutional framework for homeopathy and Ayurveda in India, continuing its efforts to rationalize the country's medical system. The Committee stated that the statutory bodies governing the education system have failed to attract qualified and qualified people based on merit due to lack of transparency.
Prices for all essential medicines are likely to increase by almost 2% from 1 April. The National Pharmaceutical Pricing Authority (NPPA) has asked companies to submit the documents required to benefit from the annual price increase based on the wholesale price index. Under the Drugs Price Control Order, the regulator revises prices of all essential medicines annually based on the changes in WPI.
Achillion Pharmaceuticals, Inc announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key mediator in the complement alternative pathway (AP).
Using genetic testing to help personalize doses of warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with clinically guided dosing, according to research presented at the American College of Cardiology’s 66th Annual Scientific Session. Researchers said these findings could have implications for a broad population of patients starting warfarin therapy.
Scientists have developed a cheap portable camera that can photograph the retina without administering the dilating pupillary irritating drops. The camera works by first emitting infrared light, iris - the muscle that controls the opening of the pupil - does not react to.
The HIV and AIDS (Prevention and Control) Bill, 2014, which aims to ensure the equal rights of people living with HIV in medical treatment, education and employment, was adopted by Discrimination on the part of the state or any other person, while providing for penal provisions for any prejudice against a person with HIV / AIDS and for breach of confidentiality.
However, during the debate on the measure, many members suggested that part of the bill be amended to delete the phrase "to the extent possible" to provide medical treatment to the Center and States to persons infected with HIV and AIDS Defying on the purpose of the move.
However, during the debate on the measure, many members suggested that part of the bill be amended to delete the phrase "to the extent possible" to provide medical treatment to the Center and States to persons infected with HIV and AIDS Defying on the purpose of the move.
The bill makes it incumbent on central and state governments to provide for anti-retroviral therapy (ART) and management of opportunistic infections (infections that take advantage of weakness in the immune system and occur frequently). The protection provided by the bill extends to the areas of employment, health services, educational services, public facilities, property rights, the public service and insurance.
The bill, proposed by the Minister of Health, J P Nadda, was adopted in the Upper House by a vote of votes. Although the bill was presented to Parliament by the UPA government, amendments to the HIV and AIDS (Prevention and Control) Bill, 2014, were revived by the Modi government last July .
For instance, the bill now makes anti-retroviral treatment a legal right for all HIV/AIDS patients. Since then, the Ministry of Health has made several amendments to the original bill to address several concerns raised by the HIV community as well as state governments.
It has also adopted "test and treat" policy which means any person testing positive will be entitled for free treatment by the state and central government. It also provides for confidentiality of HIV-related information and makes it necessary to get informed consent for undertaking HIV tests, medical treatment and research.
The Indian pharmaceutical industry must consider the January 1, 2018 deadline issued by the Comptroller General of India Drugs (DCGI) as sacrosanct to improve the skills of people employed in their units, according to the Life Sciences Sector Skill Development Council (LSSSDC) set up under the auspices of the Ministry of Skills Development.
Timely action has stopped at least 1000kilos of fake cosmetics from coming on the market at a time when the demand for sunscreens are enormous. A Girgaum man has been prosecuted by the state Food and Drug Administration (FDA) for trying to sell spurious sunscreen tubes, filled with baby lotion, under the brand name of a reputed international cosmetics company.
[adsense:336x280:8701650588]
Small and medium-sized generic drug manufacturers in India say that the threat of stricter rules and higher barriers for foreigners in the US healthcare market will force a lot to find a niche or focus their expansion efforts on other countries.
The Ministry of Health is considering setting up an online portal to regulate and fill gaps in the sale of drugs in India across all platforms, including pharmacies. "The objective of such regulation would be to ensure the availability of drugs that meet quality standards to each person in need of medicines, to curb antimicrobial resistance and to regulate the supply of drugs online, "The ministry said.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
